Adimab at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Adimab brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on de-risking therapeutic antibodies through developability profiling, off-target screening and CDR engineering. It also covers VHH bispecifics aimed at the T cell receptor constant region as an alternative to CD3 engagers.

OrganizationPEGS Europe 2026 Attendance
Adimab
Lebanon, NH
adimab.com
Discovery platforms
Discovers and engineers antibodies and bispecifics for drug developers through partnerships, using a yeast display platform.
Talk
Wed Nov 18
11:15am–11:44am
Developability Profiling, Off-Target Screening, and CDR Engineering to De-Risk Therapeutic Antibodies
Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Talk
Wed Nov 18
7:00pm–7:30pm
Chair
Thu Nov 19
2:00pm–2:05pm
Chairperson's Remarks
Novel Peptide Drug Discovery

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Adimab

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction